Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

What is Tilray Inc.?

Tilray Brands Inc. (TLRY) operates in various consumer goods sectors such as craft beer, spirits, cannabis, and hemp wellness products, with a notable international footprint. The company's stock saw significant downward movement today.

Why is Tilray Inc. going down?

TLRY stock is down 5.2% on Jun 3, 2026 16:41

• TLRY stock performed notably weaker than the broader market, declining sharply amidst industry fluctuations and expectations of potential changes in U.S. cannabis classification.
• Participation in discussions about cannabis regulations in Europe did not yield positive effects on the stock's trajectory.
• Various negative factors, including financial struggles, a high level of short selling, and reliance on U.S. federal policy shifts, influenced the bearish trend in TLRY stock.
• Despite recognition as a prominent player in the CBD market, TLRY's stock experienced a drop, breaking a recent streak of gains, which signaled investor hesitancy and a likelihood of profit-taking.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Why is Tilray Brands (TLRY) Stock Sinking Despite Market Gains

Tilray Brands (TLRY) stock has significantly underperformed the market, trading at $7.75, a steep decline from its $23.20 52-week high, largely due to sector volatility and a "buy the rumor, sell the news" reaction to U.S. cannabis reclassification hopes. Despite strategic diversification into beverages and wellness and improving adjusted EBITDA, the company faces substantial profitability challenges, high short interest, negative free cash flow, and dependence on future U.S. federal legalization, creating a high-risk, high-reward profile for investors. Analysts generally rate it a "Hold" with a median price target of $10.00.

https://www.kavout.com/market-lens/why-is-tilray-brands-tlry-stock-sinking-despite-market-gains

Tilray Brands Inc (TLRY) Joins European Talks on Cannabis Regulations

Tilray Medical, a subsidiary of Tilray Brands Inc (NASDAQ: TLRY), recently participated in discussions in London concerning medical cannabis regulations in Europe. These talks brought together healthcare professionals, researchers, industry leaders, and policymakers to advance evidence-based regulatory frameworks. Tilray Brands is a consumer packaged goods company involved in craft beer, spirits, cannabis, and hemp wellness products, with a significant international presence.

https://www.insidermonkey.com/blog/tilray-brands-inc-tlry-joins-european-talks-on-cannabis-regulations-1771886/?amp=1

Tilray Brands Inc (TLRY) Joins European Talks on Cannabis Regulations

Tilray Medical, a subsidiary of Tilray Brands Inc, recently participated in talks in London concerning medical cannabis regulations in Europe. These discussions involved healthcare professionals, researchers, industry leaders, and policymakers to advance evidence-based regulatory approaches. The company emphasizes the importance of research and clinical evidence for developing responsible frameworks and improving patient access in the evolving European medical cannabis field.

https://finance.yahoo.com/sectors/healthcare/articles/tilray-brands-inc-tlry-joins-121529453.html

5 Best CBD Stocks to Buy Right Now

This article identifies five top CBD stocks for investment, emphasizing growth potential within the evolving cannabis market. It highlights Tilray Brands Inc. (NASDAQ:TLRY) as a key player due to its medical cannabis subsidiary's involvement in European regulation talks and strong market position. The piece suggests that Tilray's diversified portfolio and international presence make it an attractive option for investors interested in the CBD sector.

https://www.insidermonkey.com/blog/5-best-cbd-stocks-to-buy-right-now-1769842/

Tilray Brands Inc. stock falls Friday, underperforms market

Tilray Brands Inc. (TLRY) shares fell 2.48% on Friday, closing at $5.51, despite an overall positive trading session for the broader market. This decline broke a three-day winning streak for the cannabis company's stock. The NASDAQ Composite Index rose 0.20%, and the Dow Jones Industrial Average gained 0.72% on the same day.

https://www.marketwatch.com/data-news/tilray-brands-inc-stock-falls-friday-underperforms-market-aa5380a0-4b26171f70bb

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.3% Today

ZCash ($ZEC) Crypto Forecast: Down 39.5% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.1% Today

XRP ($XRP) Crypto Forecast: Down 5.2% Today

NASDAQ-100 ($NDX) Index Forecast: Down 0.6% Today

Medtronic plc. ($MDT) Stock Forecast: Up 5.0% Today

SL Green Realty Corp ($SLG) Stock Forecast: Up 5.1% Today

SBA Communications Corporation ($SBAC) Stock Forecast: Up 5.0% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.1% Today

Virgin Galactic Holdings Inc ($SPCE) Stock Forecast: Up 12.6% Today

Tilray Inc. Price History

27.03.2026 - TLRY Stock was down 5.3%

• Investors opted to take profits today amidst Tilray's stock decline, following a period of volatility and speculation.
• Concerns arose among investors due to a director's sale of over 33,000 company shares, potentially impacting outlook and causing fears of dilution.
• Although positive developments such as U.S. cannabis rescheduling and the company's expansion plans emerged, the stock's decline suggests some skepticism among investors regarding the recent surge.
• Tilray's larger-than-expected quarterly loss and negative net margins may have also influenced the stock's downturn, prompting an evaluation of the company's financial standing in light of sector trends.

29.03.2026 - TLRY Stock was down 6.3%

• The stock price of Tilray dropped by 4.8% to $6.56, nearing its 52-week low and trading below its 200-day moving average, signaling bearish sentiment among investors.
• Despite the launch of new products by its subsidiary Manitoba Harvest, Tilray's stock faced continued selling pressure and technical indicators suggest a downside risk, potentially due to the company missing EPS estimates in the last quarter and reporting negative net margins.
• The underperformance of Tilray's stock compared to the broader market indices like the NASDAQ Composite and Dow Jones Industrial Average indicates specific challenges faced by the company, potentially related to its financial performance and market positioning.
• The overall US cannabis market is projected to grow significantly in the coming years, providing a positive industry outlook, but Tilray's specific stock movement today may be influenced by internal factors such as financial results and market sentiment rather than broader industry trends.

22.03.2026 - TLRY Stock was up 14.6%

• The surge in Tilray Brands Inc. (TLRY) can be linked to the filing of additional legal exhibits related to a registration statement. This move likely boosted investor confidence in the company's adherence to regulations and transparency.
• Despite the notification of an insider selling 232,872 shares, the market appeared more interested in the registration of 398,666 resalable common shares, issued for acquiring the Lyphe Group. This development hinted at potential growth avenues for the company.
• The stock's positive trajectory might also reflect a recovery from the previous day's downturn, where it performed below the market average. Investors seem to perceive this as a favorable moment to purchase following the recent price dip.
• In summary, the optimistic market sentiment surrounding Tilray Brands Inc. could stem from its regulatory compliance, growth potential from acquisitions, and a rebound from the previous day's underperformance.

08.04.2026 - TLRY Stock was down 5.1%

• TLRY's stock decline aligns with the negative trading day across the market, with the NASDAQ Composite Index and the Dow Jones Industrial Average also experiencing losses.
• The launch of Widmer Brothers' "Stay Sunny" campaign and their new beer releases may have steered investor focus and funds away from Tilray, impacting its stock performance.
• CEO Irwin Simon's positive outlook on expanding medical cannabis operations in the U.S. may not have fully offset concerns about Tilray's revenue inconsistency and ongoing losses.
• Investor uncertainties regarding the sluggish federal cannabis legalization progress and heightened competition from established beverage companies could have added to the bearish sentiment surrounding Tilray Brands Inc.

28.03.2026 - TLRY Stock was down 5.3%

• The exclusive launch of Manitoba Harvest's Superfood Smoothie Boosters at Sprouts Farmers Market suggests potential competition in the health and wellness sector, impacting investor sentiment towards Tilray.
• Concerns about growing competition and market saturation in the US cannabis market may have prompted a sell-off of TLRY shares.
• Anticipation surrounding Tilray's upcoming Q3 earnings report, which showed a wider loss than expected but beat revenue estimates, created uncertainty among investors despite the company's market outperformance.
• The market's mixed reactions to Tilray's Q3 earnings, with the stock price dropping despite surpassing revenue expectations, may have led investors to reassess the company's financial standing and future outlook.

03.05.2026 - TLRY Stock was down 5.2%

• TLRY stock performed notably weaker than the broader market, declining sharply amidst industry fluctuations and expectations of potential changes in U.S. cannabis classification.
• Participation in discussions about cannabis regulations in Europe did not yield positive effects on the stock's trajectory.
• Various negative factors, including financial struggles, a high level of short selling, and reliance on U.S. federal policy shifts, influenced the bearish trend in TLRY stock.
• Despite recognition as a prominent player in the CBD market, TLRY's stock experienced a drop, breaking a recent streak of gains, which signaled investor hesitancy and a likelihood of profit-taking.

23.03.2026 - TLRY Stock was up 8.6%

• Tilray's stock price rose by more than 30% due to discussions about the possible reclassification of cannabis, which could support the company's plans for growth in the US market.
• There is excitement among investors regarding the potential regulatory changes that could lead to tax benefits and smoother operations for cannabis firms.
• Tilray's preparedness to tap into the US medical cannabis sector after a potential reclassification showcases strategic opportunities for growth and market expansion.
• By collaborating with BrewDog USA, Tilray is demonstrating a diverse approach to innovation and product offerings, which is contributing to its optimistic market sentiment and upward trajectory.

24.03.2026 - TLRY Stock was down 12.9%

• The stock price of Tilray Brands plummeted by 11.8% following insider selling of over 33,000 shares by a director, leading to increased trading volume and negative investor sentiment.
• Despite optimism in the cannabis sector due to potential reclassification of cannabis to Schedule III, concerns about potential dilution, wider-than-expected quarterly losses, and negative net margins contributed to the bearish movement.
• While there was speculation and anticipation surrounding the Trump administration's possible rescheduling of cannabis, the lack of official confirmation led to uncertainty and a sell-off in Tilray's stock.
• Tilray's readiness to expand into the U.S. medical cannabis market post-rescheduling highlights the company's strategic positioning, but until concrete regulatory changes are announced, the stock may continue to face volatility and downward pressure.

04.04.2026 - TLRY Stock was down 5.0%

• The stock's downward trend today could be linked to Tilray's larger-than-expected EPS loss, causing investor concerns over its financial standing.
• Despite positive remarks from the CEO regarding potential benefits from US cannabis reclassification, the market reaction may stem from Tilray's current lack of cannabis sales in the US, focusing on other product lines instead.
• Analyst sentiment on Tilray remains mixed, with an average "Hold" rating and insider share selling, possibly contributing to the stock's bearish sentiment.
• Market dynamics, including the NASDAQ Composite Index uptrend and the Dow Jones Industrial Average decline, may have further driven the negative pressure on Tilray's stock.

20.04.2026 - TLRY Stock was up 5.3%

• TLRY demonstrated a strong bullish movement despite recent stock pressures.
• Investor optimism in the industry might have been sparked by discussions on cannabis rescheduling and potential regulatory shifts.
• The introduction of new nostalgia-led cocktails by BrewDog, a subsidiary of Tilray, likely positively impacted market sentiment and consumer engagement.
• Positive news and potential catalysts like cannabis legalization and the SAFE banking act may have outweighed analysts' predictions of further declines.

04.04.2026 - TLRY Stock was down 5.1%

• The company faced potential investor concerns with the launch of two new ready-to-drink cocktails by brand 10 Barrel Brewing, a Tilray subsidiary, raising worries about moving away from their core cannabis business.
• Despite surpassing revenue expectations, the stock's decline might be linked to Tilray's larger-than-expected EPS loss, creating uncertainties around the company's profitability and future growth.
• CEO Irwin Simon's positive remarks on the potential reclassification of US cannabis were overshadowed by negative factors like insider selling, stock trading below key moving averages, and overall market sentiment towards the stock.

05.04.2026 - TLRY Stock was down 6.4%

• Tilray's stock price dropped by 4.2% to $5.90, trading below key moving averages, following a wider-than-expected EPS loss of -$0.24 despite beating revenue estimates.
• The broader market also experienced losses, with the NASDAQ Composite Index dropping 0.19% and the Dow Jones Industrial Average falling 1.13%, contributing to Tilray's decline.
• The launch of two new ready-to-drink cocktails by 10 Barrel Brewing, a brand under Tilray, did not seem to positively impact the stock price, as investors may be more focused on the company's financial performance and profitability.
• Analysts' consensus "Hold" rating and lowered price targets suggest caution among investors, reflecting concerns about Tilray's current financial outlook and market conditions.